DUBLIN–(BUSINESS WIRE)–The “Global
Cancer-Induced Pain Clinical Trial Pipeline Highlights, 2019”
report has been added to ResearchAndMarkets.com’s
offering.
This report provides most up-to-date information on key pipeline
products in the global Cancer-Induced Pain market. It covers emerging
therapies for Cancer-Induced Pain in active clinical development stages
including early and late stage clinical trials.
The pipeline data presented in this report helps executives for tracking
competition, identifying partners, evaluating opportunities, formulating
business development strategies, and executing in-licensing and
out-licensing deals.
Clinical Trial Stages
The report provides Cancer-Induced Pain pipeline products by clinical
trial stages including both early and late stage development – phase 3
clinical trials, phase 2 clinical trials, phase 1 clinical trials,
preclinical research, and discovery stage.
Drug Mechanism Classes
The report provides Cancer-Induced Pain pipeline products by their
dominant mechanism of action/drug class. This helps executives
categorize products based on their drug class and also assess the
strengths and weaknesses of compounds.
Company
The report provides Cancer-Induced Pain pipeline products by the company.
Short-term Launch Highlights
Find out which Cancer-Induced Pain pipeline products will be launched in
the US and Ex-US till 2024.
Key Topics Covered
1. Cancer-Induced Pain Pipeline by Stages
2. Cancer-Induced Pain Phase 3 Clinical Trial Insights
3. Cancer-Induced Pain Phase 2 Clinical Trial Insights
4. Cancer-Induced Pain Phase 1 Clinical Trial Insights
5. Cancer-Induced Pain Preclinical Research Insights
6. Cancer-Induced Pain Discovery Stage Insights
7. Appendix
8. Research Methodology
List of Tables
Table 1: Cancer-Induced Pain Phase 3 Clinical Trials, 2019
Table 2: Cancer-Induced Pain Phase 2 Clinical Trials, 2019
Table 3: Cancer-Induced Pain Phase 1 Clinical Trials, 2019
Table 4: Cancer-Induced Pain Preclinical Research, 2019
Table 5: Cancer-Induced Pain Discovery Stage, 2019
List of Figures
Figure 1: Cancer-Induced Pain Pipeline Molecules by Clinical Trials
Stage, 2019
Figure 2: Cancer-Induced Pain Phase 3 Clinical Trial Highlights, 2019
Figure 3: Cancer-Induced Pain Phase 2 Clinical Trial Highlights, 2019
Figure 4: Cancer-Induced Pain Phase 1 Clinical Trial Highlights, 2019
Figure 5: Cancer-Induced Pain Preclinical Research Highlights, 2019
Figure 6: Cancer-Induced Pain Discovery Stage Highlights, 2019
For more information about this report visit https://www.researchandmarkets.com/r/8jlpmd
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs, Analgesics,
Clinical
Trials